Poster at ECCMID 2021:
K.S. Jensen, P.G. Cojutti, T. Katsube, C. Longshaw, A.S. Henriksen, F. Pea

A retrospective analysis of the probability of target attainment for cefiderocol versus other antibacterial agents for resistant Gram negative infections

Summary:

In this study, PTAs and CFRs in the same simulated population are compared for four approved antibacterial agents  – cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem –  against the WHO critical priority pathogens Enterobacterales, P. aeruginosa, and ACB complex. PK models for all therapies were selected from published PK models identified in the literature, and validated to verify that they could reproduce selected cases of the original published simulation results. Targets related to efficacy against the selected pathogens for all simulated antibacterial agents were fT>MIC (or fT>minimum effective concentration [MEC] for the beta lactamase inhibitors avibactam and tazobactam).

Cefiderocol demonstrated higher CFRs than ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem for all three pathogens, with values >90% for each.

Additional search terms: in silico comparative study, Monte Carlo simulation, standard virtual population, cumulative fraction of response.